• SAN DIEGO, January 9, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:) () announced today that Chairman, President and Chief Executive Officer, Dr. Bassam Damaj's previously announced presentation, taking place at 2:30pm Pacific Time today, at Biotech Showcase™ 2012 at the Park Wyndham Hotel in San Francisco, California, will be webcast. Interested parties may access the live webcast (including audio and slides) at the Company's website, . A webcast replay will be available beginning two hours after the Company's live webcast presentation by following the same links.

    About the Biotech Showcase™

    Now in its fourth year, Biotech Showcase™ will feature corporate presentations by 200+ innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. The showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all showcase participants can schedule one-on-one meetings through the organizer's online system, partneringONE®. Public and private investors are always invited to attend the showcase on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life sciences industry. Visit their website for more information: .

    About Apricus Biosciences, Inc.

    Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes.

    Revenues and growth are driven from the sales of the Company's commercial products and out-licensing in certain territories of its product pipeline and NexACT® technology. The company's pipeline includes Vitaros®, approved in Canada for the treatment of erectile dysfunction, Totect the only drug approved in the US for the treatment of anthracycline extravasation, as well as compounds in development from pre-clinical through pre-registration, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare.

    The Company also expects to develop and/or acquire and then bring to market additional pharmaceutical products in areas of care that will benefit patient needs worldwide.

    ,for information on its subsidiary please visit .

    Apricus Bio's Forward-Looking Statement Safe Harbor

    Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to receive issued patents on its NexACT® technology and products, develop such patented technology into product candidates, have its Rx Division products and product candidates such as Vitaros® approved by relevant regulatory authorities and its Consumer Healthcare Division products either approved or cleared by relevant regulatory authorities or be in compliance with appropriate regulatory requirements, to successfully manufacture and commercialize such Rx Division products in the U.S., Canada, Europe and in other countries along with its Consumer Healthcare Division products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

    Contacts:

    Apricus Biosciences, Inc.
    Edward Cox, V.P.

    Investor Relations & Corporate Development Apricus Bio, Inc.
    (858) 848-4249
    ecox@apricusbio.com

    Apricus BioInvestor Relations
    Paula Schwartz

    Apricus Bio, Inc. Rx Communications Group, LLC
    (917) 322-2216
    pschwartz@rxir.com
distribué par

Ce noodl a été diffusé par Apricus Bioscience Inc. et initialement mise en ligne sur le site http://www.apricusbio.com. La version originale est disponible ici.

Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-09 22:51:15 PM et restera accessible depuis ce lien permanent.

Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.